With so many different oncology alternative payment models (APMs) available, choosing the right ones to participate in might simply mean finding which ones already align with what a practice is doing, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
With so many different oncology alternative payment models (APMs) available, choosing the right ones to participate in might simply mean finding which ones already align with what a practice is doing, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Transcript
Recently, the Community Oncology Alliance released a report that there are more than 30 oncology-related APMs. How does Northwest Medical Specialties determine which model to participate in?
There's a lot of different APMs out there. And what we really try to do is look at the quality measures that that specific APM is requiring, or that specific payer, and how it aligns with our current programs. We don't want to get into a situation where we have 15 different programs with 15 different quality measure rules and methodologies, because there is a lot of administrative burden that takes place behind the scenes of all of these APMs, whether that be, you know, billing out the MEOS [Monthly Enhanced Oncology Services], or tracking the patients—all of these different things.
So, what we really try to do is find out what's aligned with what we're already doing. And of course, there's some wiggle room. If there's something that's trying to introduce a new measure for us, or maybe has a slightly different methodology, we're open to that. But when you get into a space where you have these completely different models, that means you may need more staff to support those models. I think those are the really the key things that we look at is really alignment between the models.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More